Singapore markets close in 5 hours 36 minutes

GSK plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
1,423.60+22.40 (+1.60%)
At close: 05:59PM BST
Full screen
Previous close1,401.20
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Avg. volume10,161,640
Market cap59.818B
Beta (5Y monthly)0.27
PE ratio (TTM)13.43
Earnings dateN/A
Forward dividend & yield0.61 (4.26%)
Ex-dividend date23 Feb 2023
1y target estN/A
  • Motley Fool

    Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?

    No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization. Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it. One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized.

  • Zacks

    Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?

    Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • Motley Fool

    Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?

    Earlier this month, GSK's (NYSE: GSK) older-adult vaccine candidate for respiratory syncytial virus (RSV) moved one step closer to approval. The U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee voted unanimously (12 to 0) in favor of the vaccine's efficacy and 10 to 2 in favor of its safety. With a decision expected from the FDA by May, the vaccine candidate could launch in time for the next RSV season.